A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Items 601–638 of 638
Pagliaccio, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_104-1
Severe Obsessive‒compulsive Disorder of Transformation in a 13-year-old Adolescent: A Case Report
Kerkeni, A., & Pons, C. O. (2025) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822351945241215171316
Obsessive-Compulsive Disorder in Childhood and Adolescence
Højgaard, D. R. M. A., & Skarphéðinsson, G. (2025) · Springer eBooks · doi:10.1007/978-3-031-40858-8_200-1
Gill, C. S., Dailey, S. F., Karl, S. L., & Minton, C. A. B. (2025) · Wiley eBooks · doi:10.1002/9781394346684.part2a
Prescribing in Children and Adolescents
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg005.pub2
Obsesif-Kompulsif Hastalıklar - Tanı ve Tedavileri
Gül, V. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3672
Tics and Tic‐Like Phenomena as Compulsive Acts
Grippe, T. C., Chen, C., Balachandar, A., Reyes, N. G. D., Sandor, P., Lang, A. E., & Ganos, C. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70264
Pagliaccio, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_104
Uğuz, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-99720-4_18
Innovative treatment approaches for paediatric obsessive-compulsive disorder
Marazziti, D., Gurrieri, R., Gambini, M., Russomanno, G., Palagini, L., & Mucci, F. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2591073
Treatment of anxiety: current status and controversial issues
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.024
Rus, O. G. (2017) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.21593
Chouhan, A., Rawat, M., & Sandhu, S. (2026) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251414904
“13 CBT, particularly ERP, was administered in both twin pairs and adapted to their predominant symptom clusters, in keeping with best-practice recommendations.”
Adegbola, A., Dhir, N., & Ogunjobi, O. (2026) · Cureus · doi:10.7759/cureus.102813
“Bloch et al., in a systematic review of antipsychotic augmentation of treatment refractory OCD, reported that there is sufficient evidence supporting the efficacy of haloperidol and risperidone while the efficacy of other antipsychotics like quetiapine and olanzapine is unclear [14].”
Salvi, J. D. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1745041
Neurocognition in Obsessive-Compulsive Disorder
Baer, J. (2024) · TSpace (University of Toronto)
Kawahito, M., Murayama, K., Tomiyama, H., Kato, K., Matsukuma, K., Nishida, N., Kamio, T., Tsunoda, K., Sashikata, K., Kang, M., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1774594
Nguyen, T. H. (2011) · theses.fr (ABES) · doi:10.70675/95d75bd8zdd5bz4677zaf98zc9268bd885f9 · Cited by 2
Mondragón-González, S. L. (2019) · theses.fr (ABES) · doi:10.70675/e78705daz18a9z4695zac41zadeb07ee7c37
Tricky “Ticcy” Case: Tics/Tourette Syndrome with Co-occurring OCD
Ebner, L., Kaylor, A., Essa, A., Greenberg, E., & Scharf, J. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-10099-3_3
Artificial Intelligence-focused Obsessions Evolving into Delusion-like Beliefs
Haque, R., Sharma, S., Modi, R., & Bansal, D. D. (2026) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_375_25
Medicinal plants for obsessive-compulsive disorder: A review of phytotherapeutic approaches
Devaraja Dravida Pandiyan, S., Jeyabalan, S., Subramaniyan, V., Balu, A., Wong, L. S., Sekar, M., & Ashok, C. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.05.011 · Cited by 1
Hadžić, T., Lulla, A., & Nurmi, E. L. (2026) · Current Developmental Disorders Reports · doi:10.1007/s40474-026-00353-6
“SSRIs remain first-line, but the presence of tics may justify antipsychotic augmentation [35, 51].”
Cheung, H. K., & Cheung, N. (2026) · Cureus · doi:10.7759/cureus.112492
“…differentiation and reduction of overvalued ideas occurred after risperidone was increased from 0.25 mg to 1 mg. Risperidone has evidence as an augmentation strategy in treatment-resistant OCD and related presentations, especially when intrusive or overvalued content is prominent [21-23].”
InfluentialWagner, K. M., Cheng, J. S. C., Moore, H. C., Li, D., Ahmad, M., Tonarelli, S. B., Cervin, M., Nicolini, H., Muñoz, J. S., Anderberg, J. L., et al. (2026) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2026.101030
Hudak, R., Eken, H. N., & Donahue, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00006-6
Neurochemistry and neurotransmitters involved in obsessive–compulsive disorder
Grant, J. E., & Sohl, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00004-2
Martínez-Montero, M., González-Domenech, P., Romera, I., Moleón-Ruiz, Á., García, M. M.-B., Gutiérrez-Rojas, L., & Jiménez‐Fernández, S. (2026) · Psychiatric Quarterly · doi:10.1007/s11126-026-10309-z
Antipsychotics in Anxiety Disorders and Obsessive-compulsive Disorder in Children and Adolescents
Rajalakshmi, A. K., & Greenberg, E. (2026) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2026.07.005
Bhupathiraju, N., Lara, L., Bahadorkhan, A., Vidal, G., & Tonarelli, S. B. (2026) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2026.100197
Albukhari, A. F. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06216-w
“Rather than replacing serotonergic modulation, this approach targets a parallel regulatory system involved in action selection and behavioral flexibility [45, 153, 154].”
Ganzevoort, C. O. W., Hornstra, R., Wolters, L. H., Isaksen, C. S., Smárason, O., Hybel, K. A., Højgaard, D. R. M. A., Skarphéðinsson, G., Kreuze, L. J., & Nauta, M. H. (2026) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-026-03192-3
Pickenhan, L. (2026) · Apollo (University of Cambridge) · doi:10.17863/cam.135532
Silvianingrum, R. (2026) · Jurnal Sehat Indonesia (JUSINDO) · doi:10.59141/-.v8i2.582
“The sharp decline from 34 to 17 in a span of several days was less consistent with the course of the GOK therapy response, which generally takes weeks, especially since the patient was still at the initiation dose.”
InfluentialDiscordant phenotypes of obsessive-compulsive disorder (OCD) in twins
Rawat, M., Chouhan, A., & Pal, V. S. (2026) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_478_24
Neuroscience-informed psychoeducation for OCD
McLaughlin, N. C. R., Fedorenko, E. J., & Kulak, M. J. (2026) · Progress in brain research · doi:10.1016/bs.pbr.2026.10.002
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.